certolizumab
ucb pharmaceuticals
['certolizumab', 'axspa']
potential disconnect: objective inflammatory response, oir (mri/crp levels) vs clinical response,cr (basdai/asdas). post hoc analysis axspa on certolizumab. majority of patients &gt;50% improved oir, only minority improved cr. rudwaleit etal #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach